Guillem Jorba

TPMS technology to infer biomarkers of macular degeneration prognosis in in silico simulated prototype-patients under the study of heart failure treatment with sacubitril and valsartan

Albert Pujol, B. Oliva, N. Fernandez-Fuentes, 2019, bioRxiv.

The usage of transcriptomics datasets as sources of Real-World Data for clinical trialling

J. Farrés, J. Mas, Guillem Jorba, 2022, bioRxiv.

Methods to Develop an in silico Clinical Trial: Computational Head-to-Head Comparison of Lisdexamfetamine and Methylphenidate

X. Daura, J. Quintero, J. Mas, 2021, Frontiers in Psychiatry.

Targeting autophagy in disease: established and new strategies

J. Farrés, Ana Martínez, V. Kirkin, 2021, Autophagy.

Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an in silico systems biology-based approach

J. Mas, Guillem Jorba, C. Segú-Vergés, 2021, Oncotarget.

In-silico simulated prototype-patients using TPMS technology to study a potential adverse effect of sacubitril and valsartan

Valentin Junet, Joaquim Aguirre-Plans, Baldo Oliva, 2020, PloS one.

A quantitative systems pharmacology model for certolizumab pegol treatment in moderate-to-severe psoriasis

P. Coto-Segura, Guillem Jorba, C. Segú-Vergés, 2023, Frontiers in immunology.